The companies are co-developing an assay that differentiates previously infected, seropositive Lyme disease patients from newly infected individuals.
The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.
In separate deals announced this past week, the German biotech firm will distribute assays developed by Asuragen, and co-develop, co-manufacture, and co-market assays with Mikrogen.
The company is collaborating with fellow German biotech firm Mikrogen to identify autoantibody signatures typical of various infectious diseases.
The German firms said this week that they have conducted a feasibility study for identifying autoantibody signatures in infectious diseases that may be useful for future diagnostics.
The firms are working on infectious disease diagnostics using Protagen's UNIarray platform.
Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.
Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.
The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.
In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.